Medtronic and DASI Simulations have announced a strategic partnership to enhance access to DASI technology to optimise outcomes for patients undergoing transcatheter aortic valve implantation (TAVI) in the USA.
By integrating DASI Simulations’ advanced AI-based predictive modelling and digital twin technology into the TAVI workflow, clinicians will gain access to independent and device-agnostic actionable insights that support more precise, individualised treatment decisions for patients living with aortic stenosis, the organisations said in a press release.
“Effective pre-case planning is essential to achieving optimal outcomes in TAVI,” said Matthew Summers, interventional cardiologist at Sentara Heart Hospital, Norfolk, USA. “Integrating DASI’s predictive modelling into our workflow has allowed us to better visualise anatomy, anticipate risks, and tailor valve decisions to each patient. It’s helped us focus on individual factors like annular rupture, coronary occlusion, and paravalvular leak, while also planning for future reinterventions. As TAVI complexity grows, it becomes increasingly important to have tools that support truly personalised decision-making. This includes making informed choices between surgical aortic valve replacement and TAVI, as well as which TAVI valve, to ensure the best possible care.”
“Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide,” said Teri Sirset, founder, president, and chief executive officer of DASI Simulations. “Together, we’re demonstrating how predictive modelling can drive operational efficiency, support clinical decision-making, and elevate the standard of care. This collaboration reflects the growing demand for data-driven solutions that empower heart teams to deliver more confident, personalised treatment decisions.”
DASI’s US Food and Drug Administration (FDA)-cleared platform leverages real patient computed tomography (CT) anatomies and retrospective outcomes to simulate multiple transcatheter heart valve (THV) deployment scenarios. Using these data-driven reports will help mitigate human error, predict complications, and optimise long-term management for structural heart patients, the press release adds.
“The future of TAVI lies in delivering patient-specific, data-driven care that spans the full patient journey, from therapy awareness and innovation to procedural excellence and options for future intervention,” said Jorie Soskin, vice president and general manager of the Structural Heart business within the Cardiovascular portfolio at Medtronic. “Our partnership highlights our commitment to lead this future, allowing heart teams to utilise AI driven pre-procedural planning to enhance patient outcomes, streamline workflow, and support patient-specific valve selection.”
Participating sites will receive full support from both Medtronic Structural Heart and DASI Simulations teams. The programme is designed to demonstrate the clinical and operational value of integrating simulation-based planning to enable device agnostic, patient-specific TAVI care.
“We are entering a new era in structural heart care, guided by predictive AI models that help the physician determine the best treatment personalised for each patient, rather than relying on statistical norms. This shift to precision medicine will transform how we treat structural heart diseases,” said Lakshmi Dasi, founder and chief technology officer at DASI Simulations. “DASI is the pioneer for AI-based predictive modelling for TAVI, and our platform is designed to support unbiased and device agnostic decision-making with the patient at the centre that will ultimately support more confident, personalised interventions.”
